human
cytomegaloviru
hcmv
ubiquit
herpesviru
abl
infect
fibroblast
epitheli
endotheli
hematopoiet
cell
past
ten
year
sever
group
provid
direct
evid
dendrit
cell
dc
fulli
support
hcmv
lytic
cycl
previous
demonstr
ctype
lectin
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
promin
role
dock
hcmv
monocytederiv
dc
mddc
dcsignhcmv
interact
demonstr
crucial
earli
event
substanti
enhanc
infect
tran
ie
one
cmvbear
cell
anoth
noninfect
cell
transinfect
render
suscept
cell
fulli
permiss
hcmv
infect
nevertheless
noth
yet
known
hcmv
enter
mddc
studi
demonstr
vhle
hcmv
virion
endotheliodendrotrop
strain
first
intern
mddc
macropinocytosislik
process
actinand
cholesteroldepend
phindepend
manner
observ
accumul
virion
larg
uncoat
vesicl
endosom
featur
virion
remain
intact
particl
retain
infecti
potenti
sever
hour
transinfect
properti
specif
mddc
monocytederiv
macrophag
monocyt
donor
unabl
allow
accumul
subsequ
transmiss
viru
togeth
data
allow
us
delin
earli
mechan
intern
entri
endotheliodendrotrop
hcmv
strain
human
mddc
propos
dc
serv
trojan
hors
convey
cmv
entri
site
locat
may
favor
occurr
either
latenc
acut
infect
citat
haspot
f
lavault
sinzger
c
laib
sampaio
k
stierhof
yd
et
al
human
cytomegaloviru
entri
dendrit
cell
occur
via
macropinocytosislik
pathway
phindepend
cholesteroldepend
manner
plo
one
human
cytomegaloviru
hcmv
infect
virtual
target
cell
human
origin
howev
viral
transmiss
system
spread
prolifer
occur
differ
cell
type
epitheli
cell
endotheli
hematopoiet
cell
fibroblast
smooth
muscl
cell
respect
see
review
hcmv
initi
infect
nonspecif
lowavid
interact
heparan
sulfat
proteoglycan
hspg
higher
avid
receptor
annexin
ii
egfr
integrin
shown
promot
stabl
attach
vari
degre
receptor
inde
shown
play
minor
role
even
role
hcmv
captur
entri
except
integrin
lesser
extent
integrin
inde
integrin
shown
interact
hcmv
particl
trigger
intracellular
signal
disintegrinlik
motif
envelop
glycoprotein
b
hcmv
gb
interestingli
previous
report
hcmv
gb
also
ligand
ctype
lectin
receptor
dendrit
cell
dc
specif
icamgrab
nonintegrin
dcsign
demonstr
dcsign
contribut
crucial
blockad
dcsign
antibodymedi
neutral
necessari
suffici
dramat
reduc
reduct
bind
hcmv
cell
surfac
impair
product
infect
mddc
hcmv
appear
hcmv
like
use
distinct
cell
surfac
receptor
dock
entrymedi
properti
depend
target
cell
anim
virus
enter
host
cell
directli
penetr
ie
releas
viral
capsid
cytosol
fusion
viral
envelop
plasma
membran
major
depend
endocyt
uptak
follow
viral
penetr
endosom
level
endocytosi
process
cell
engulf
molecul
pass
plasma
membran
endocytosi
occur
via
differ
mecan
involv
uptak
fluid
solut
small
particl
viru
entri
endocytosi
shown
involv
clathrin
lipid
raft
well
geec
flotillin
pathway
macropinocytosi
phagocytosi
see
review
macropinocytosi
defin
actindepend
endocyt
process
involv
plasma
membran
ruffl
allow
intern
fluid
particl
larg
uncoat
endocyt
vesicl
see
review
step
hcmv
intern
partial
elucid
appear
vari
accord
hcmv
strain
tropism
type
target
cell
although
hcmv
entri
fibroblast
epitheli
endotheli
cell
shown
use
distinct
pathway
noth
known
entri
hcmv
dendrit
cell
dc
notic
fibroblast
infect
independ
actin
polymer
wherea
infect
endotheli
cell
retin
pigment
epitheli
cell
rpe
actindepend
hcmv
enter
fibroblast
direct
fusion
plasma
membran
phindepend
manner
wildtyp
tr
strain
enter
epitheli
endotheli
cell
endocytosi
process
fusion
requir
endosom
acidif
furthermor
shown
hcmv
enter
rpe
cell
two
distinct
pathway
depend
cell
type
viru
produc
viru
produc
epitheli
cell
preferenti
enter
target
rpe
cell
via
fusion
plasma
membran
wherea
virion
gener
fibroblast
enter
endocytosi
recent
paper
also
demonstr
import
intact
region
hcmv
monocyt
infect
use
electron
microscopi
show
accumul
hcmv
virion
larg
vacuol
suggest
hcmv
may
enter
monocyt
direct
fusion
plasma
membran
immatur
dc
known
profession
antigen
present
cell
apc
character
high
endocyt
capac
allow
antigen
uptak
process
review
see
altern
fundament
properti
may
use
envelop
virus
effici
penetr
cell
thu
partli
prevent
lysosom
degrad
detect
neutral
immun
system
allow
releas
viral
genet
materi
close
target
cell
nucleu
requir
locat
initi
viral
replic
review
see
base
abil
hcmv
interact
dcsign
endeavor
demonstr
highli
endotheliotrop
hcmv
strain
vhle
also
known
leukotrop
even
dendrotrop
intern
enter
monocytederiv
dc
mddc
present
evid
vhle
virion
intern
entri
mddc
occur
via
macropinocytosislik
pathway
cholesteroldepend
phindepend
manner
entri
pathway
shown
particip
transmiss
viru
dc
target
cell
also
known
transinfect
human
fresh
blood
sampl
obtain
etabliss
du
sang
french
blood
donor
bank
ef
nant
franc
human
cell
use
studi
prepar
healthi
human
volunt
consequ
ethic
statement
requir
work
peripher
blood
mononuclear
cell
pbmc
isol
whole
blood
densiti
centrifug
ficollpaqu
eurobio
le
uli
franc
differ
cell
popul
enrich
pbmc
counterflow
centrifug
elutri
use
beckman
avanti
centrifug
equip
rotor
ml
elutri
chamber
beckman
instrument
inc
fullerton
usa
introduct
pbmc
suspens
remain
platelet
red
cell
elutri
first
flow
rate
increas
order
collect
lymphocyt
final
monocyt
elutri
human
monocyt
use
gener
immatur
dendrit
cell
accord
protocol
describ
sallusto
colleagu
cell
pure
seed
cell
per
ml
rpmi
fetal
calf
serum
mm
glutamin
supplement
ngml
rhgmcsf
gentaur
pari
franc
ngml
cellgenix
freiburg
germani
cultur
five
seven
day
fulli
differenti
immatur
dc
display
follow
standard
phenotyp
neg
hladr
low
low
neg
assess
use
fluorescein
isothiocyanateconjug
fitcconjug
antibodi
bd
bioscienc
ca
usa
monocyt
derivedmacrophag
type
macrophag
obtain
monocyt
cultur
day
gmcsf
describ
previous
human
foreskin
fibroblast
hff
obtain
depart
immunolog
dermatolog
pr
b
dreno
chu
nant
franc
hff
propag
fetal
calf
serum
mm
lglutamin
media
recombin
solubl
hcmv
glycoprotein
b
rec
hcmv
gb
kind
gift
franc
dapi
alexafluor
transferrin
alexafluor
alexafluor
goat
antimous
igg
mab
obtain
molecular
probe
eugen
usa
dmso
n
ndimethyl
amilorid
hydrochlorid
dma
cytochalasin
bafilomycin
chlorpromazin
filipin
nystatin
methylbcyclodextrin
ammonium
chlorid
rottlerin
purchas
sigma
aldrich
st
loui
mo
usa
calbiochem
san
diego
ca
usa
conjug
antibodi
hladr
well
purifi
transferrin
receptor
dcsign
clone
pharmingen
bd
bioscienc
ca
usa
fitcconjug
monoclon
antibodi
obtain
pharmingen
transduct
laboratori
respect
bd
bioscienc
usa
unconjug
antihcmv
glycoprotein
b
antibodi
clone
use
confoc
imag
western
blot
detect
respect
purchas
abcam
cambridg
uk
endotheliotrop
human
hcmv
strain
vhle
use
studi
publish
work
viru
propag
purifi
titer
describ
elsewher
briefli
gradient
purif
vhle
virion
perform
infecti
supernat
infect
hff
cultur
approxim
latestag
cytopath
effect
made
cell
free
centrifug
ten
minut
g
supernat
ultracentrifug
minut
g
pellet
contain
virion
particl
resuspend
ml
phosphatebuff
salin
pb
transfer
onto
preform
linear
glyceroltartr
gradient
sodium
tartrat
glycerol
sodium
phosphat
ultracentrifug
minut
g
virioncontain
band
harvest
syring
virion
wash
pellet
addit
ultracentrifug
step
minut
g
pellet
resuspend
store
use
infect
experi
qualiti
viral
stock
assess
neg
contrast
transmiss
electron
microscopi
supplementari
figur
usual
intact
envelop
virion
account
physic
particl
purif
quantif
viru
assess
plaqueform
assay
hff
viral
dna
extract
use
nucleospinh
rna
viru
kit
macherey
nagel
franc
accord
manufactur
instruct
bp
fragment
viral
gene
amplifi
use
quantit
real
time
pcr
oligonucleotid
probe
use
assay
follow
forward
revers
tamra
cmvsrg
order
exclud
falseneg
result
intern
amplif
control
includ
reaction
taqmanh
exogen
intern
posit
control
reagent
ipc
cmv
dna
quantit
achiev
standard
curv
gener
serial
dilut
plasmid
contain
viral
target
sequenc
hcmv
dna
load
express
absolut
dna
copi
number
day
immatur
mddc
either
treat
appropri
drug
minut
cell
infect
hcmv
moi
recombin
hcmv
gb
mgml
variou
period
time
thereaft
cell
wash
three
time
pb
allow
settl
least
minut
polyllysineco
coverslip
overnight
pretreat
mgml
pb
four
degre
celsiu
fix
ten
minut
paraformaldehyd
pfa
pb
altern
cell
wash
glycinebas
acid
buffer
ph
immedi
incub
step
hcmv
remov
cellassoci
virion
wash
pb
permeabil
room
temperatur
ten
minut
pb
contain
triton
cell
label
appropri
primari
secondari
antibodi
list
mount
fluoromount
medium
dako
nuclei
counterstain
dapi
need
imag
acquir
immers
oil
magnif
confoc
microscop
microsystem
germani
tem
perform
electron
microscopi
facil
feder
institut
research
nant
franc
briefli
day
mddc
treat
medium
alon
inhibitor
desir
concentr
incub
vhle
moi
vari
time
period
minut
two
six
hour
cell
wash
without
addit
acid
buffer
inactiv
step
resuspend
fix
solut
glutaraldehyd
vv
sorensen
phosphat
buffer
two
hour
half
cell
wash
postfix
wv
osmium
tetroxid
one
hour
dehydr
ethanol
embed
epon
resin
mixtur
ultrathin
section
doublestain
use
uranyl
acet
lead
citrat
final
thin
section
nm
cut
reichert
ultracut
e
microtom
doublestain
use
uranyl
acet
lead
citrat
observ
contrast
section
done
kv
transmiss
electron
microscop
jeol
one
two
hundr
thousand
immatur
mddc
per
condit
treat
variou
dose
inhibitor
minut
incub
endotheliotrop
hcmv
strain
vhle
moi
two
addit
hour
thereaft
nonintern
viral
particl
remov
three
wash
step
one
lowph
glycin
buffer
infect
cell
subcultur
hour
condit
cell
aliquot
kept
assess
cell
viabil
flow
cytometri
use
propidium
iodid
dapi
drug
concentr
use
alter
cell
viabil
data
shown
cell
allow
adher
polyllysineco
coverslip
prior
fix
permeabil
aceton
label
minut
specif
mab
direct
immediateearli
earli
hcmv
antigen
mab
antiiea
argen
biosoft
varilh
franc
goat
antimous
igg
polyclon
antibodi
conjug
horseradish
peroxidas
dako
subsequ
appli
minut
step
slide
wash
twice
pb
five
minut
presenc
antigen
visual
stain
aminoethyl
carbazol
aec
argen
biosoft
minut
ten
minut
wash
dh
slide
counterstain
hematoxylin
sigma
mount
glycerolgelatin
sigma
specimen
incub
isotyp
antibodi
dako
use
neg
control
slide
analyz
use
computerbas
optic
imag
analyz
eclips
nikon
nikon
instrument
inc
ny
usa
analys
perform
magnif
four
distinct
field
situat
mm
apart
infect
rate
calcul
mean
valu
number
infect
cell
count
four
distinct
field
per
condit
divid
mean
valu
total
number
count
cell
multipli
semiautom
count
done
use
imagej
softwar
determin
locat
intern
hcmv
virion
mddc
adapt
subcellular
fraction
assay
segura
colleagu
briefli
immatur
mddc
cell
per
condit
incub
vhle
moi
two
hour
one
acid
buffer
inactiv
three
addit
wash
pb
cell
homogen
cellcrack
kimbl
chase
life
scienc
nj
usa
homogen
buffer
pb
sucros
mm
tri
mm
edta
supplement
proteas
inhibitor
purchas
roch
ph
postnuclear
supernat
pn
prepar
centrifug
ten
minut
load
top
percol
ge
healthcar
solut
homogen
buffer
ultracentrifug
g
minut
one
ml
fraction
collect
top
three
fraction
earli
endosom
pool
concentr
ultracentrifug
g
one
hour
bottom
two
fraction
pool
load
top
percol
solut
homogen
buffer
ultracentrifug
minut
top
three
fraction
late
endosom
bottom
two
fraction
lysosom
pool
concentr
ultracentrifug
g
one
hour
need
collect
fraction
pool
concentr
onto
filtrat
devic
cutoff
kda
millipor
bedford
usa
frozen
use
instantli
analyz
western
blot
protein
content
subcellular
fraction
quantifi
bca
assay
sigma
accord
manufactur
instruct
absenc
conserv
refer
protein
subcellular
fraction
obtain
cell
fraction
equal
amount
total
protein
load
sdspage
gel
pierc
biotechnolog
day
frozen
monocyt
healthi
human
volunt
thaw
differenti
five
day
toward
mddc
macrophag
see
cell
reagent
part
materi
method
section
inform
day
anoth
vial
monocyt
healthi
volunt
thaw
three
cell
type
cultur
minut
without
bafilomycin
cell
infect
hcmv
moi
two
hour
afterward
extens
wash
pb
lowph
buffer
infect
cell
cocultur
close
contact
fibroblast
monolay
fourtyeight
hour
fibroblast
process
label
describ
cytomegaloviru
infect
inhibit
assay
evalu
transinfect
hcmvload
cell
statist
analysi
perform
use
nonparametr
mannwhitney
test
prism
graphpad
softwar
p
valu
less
consid
signific
identifi
point
entri
hcmv
particl
mddc
analyz
mddc
shortterm
hcmv
infect
two
hour
transmiss
electron
microscopi
tem
first
note
hcmv
particl
partli
surround
cell
membran
ruffl
suggest
actin
polymer
need
allow
membran
remodel
engulf
hcmv
virion
figur
also
observ
vesicl
content
hcmv
virion
either
transpar
moder
dens
electron
suggest
virion
may
accumul
earli
endocyt
vesicl
vari
phenotyp
like
distinct
properti
figur
dens
bodi
also
observ
mix
infecti
particl
might
behav
entri
intact
particl
due
envelop
similar
infecti
virion
kinet
mddc
infect
allow
us
quantifi
hcmv
virion
locat
yet
unknown
vacuol
insid
cell
virion
still
bound
plasma
membran
figur
six
hour
postinfect
virion
detect
local
insid
cell
figur
test
whether
hcmv
intern
actindepend
process
use
cytoskeleton
pharmacolog
inhibitor
abl
prevent
actin
polymer
analyz
effect
inhibitor
cmv
infect
mddc
downstream
event
viral
entri
day
six
mddc
pretreat
increas
concentr
actin
inhibitor
vehicl
control
minut
prior
infect
hcmv
moi
two
hour
extens
wash
follow
hour
cultur
cell
stain
hcmv
iee
nuclear
antigen
counterstain
hematoxylin
allow
total
cell
count
simultan
cell
viabil
assess
condit
flow
cytometr
analysi
dapi
propidium
iodid
exclus
data
shown
pretreat
cytochalasin
mm
figur
latrunculin
mm
data
shown
infect
mddc
hcmv
significantli
impair
compar
dmsotreat
vehicl
nontreat
cell
figur
confirm
actin
remodel
necessari
hcmv
engulf
mddc
sought
identifi
natur
larg
vesicl
contain
intern
hcmv
particl
describ
previous
purpos
infect
immobil
mddc
vhle
strain
three
hour
cell
fix
permeabil
label
character
locat
hcmv
red
stain
differ
type
organel
identifi
earli
endosom
antigen
marker
green
stain
preferenti
express
earli
late
endosom
lysosom
respect
pictur
obtain
confoc
imag
display
figur
analyz
imagej
rgb
profil
pluge
time
point
observ
coloc
hcmv
suggest
viru
intern
larg
endocyt
vesicl
match
featur
earli
late
endosom
surprisingli
unabl
observ
coloc
hcmv
stain
time
point
perform
subcellular
fraction
extract
enrich
earlyl
endosom
eel
lysosom
ly
separ
qualiti
assess
western
blot
use
antibodi
perform
experi
use
hcmvinfect
mddc
two
hour
moi
firstli
look
presenc
two
viral
protein
envelop
protein
gb
kda
mcp
major
capsid
compon
kda
within
test
fraction
figur
viral
antigen
found
expect
molecular
weight
kda
mcp
kda
gb
earli
late
endosomecontain
fraction
neither
mcp
gb
could
evidenc
pn
fraction
like
due
lack
sensit
western
blot
assay
sinc
obtain
endosomesor
lysosomesenrich
fraction
ca
ml
pn
fraction
ml
concentr
ly
gb
detect
protein
lower
molecular
weight
compar
recombin
gb
addit
rel
amount
gb
ly
fraction
appear
diminish
compar
eel
fraction
sinc
equal
amount
protein
load
gel
suggest
degrad
viral
gb
may
initi
moreov
mcp
detect
lysosomeenrich
fraction
secondli
quantifi
hcmv
genom
copi
number
subcellular
fraction
quantit
pcr
supplementari
figur
hcmv
genom
dna
could
detect
fraction
contain
earli
late
endosom
well
lysosom
result
go
line
coloc
studi
describ
previous
figur
may
suggest
viral
penetr
could
occur
lysosom
stage
onto
polyllysineco
slide
fix
permeabil
aceton
stain
mab
antii
e
antigen
argen
biosoft
franc
four
distinct
field
digit
analyz
imagej
softwar
determin
percentag
ieaea
mddc
n
independ
experi
eight
differ
donor
total
order
fulli
demonstr
intern
hcmv
particl
infect
mddc
care
analyz
ultrathin
section
mddc
inocul
six
hour
vhle
particl
evid
presenc
uncoat
capsid
mddc
cytoplasm
thu
substanti
number
cell
simultan
observ
vast
major
intact
virion
within
vesicl
structur
resembl
uncoat
capsid
cytosol
figur
remark
nake
capsid
usual
found
proxim
nuclear
envelop
figur
observ
strongli
suggest
least
intern
hcmv
particl
underw
penetr
uncoat
releas
capsid
cytoplasm
may
gain
access
nuclear
pore
inject
dna
nucleu
finali
compar
intern
whole
hcmv
particl
virusfre
recombin
solubl
gb
abl
bind
dcsign
observ
wherea
recombin
gb
complet
convey
lysosom
minut
complet
coloc
whole
hcmv
virion
never
coloc
lysosom
marker
supplementari
figur
b
suggest
could
sequest
previous
describ
vesicl
although
differ
term
size
molecular
orient
andor
multimer
hcmv
particl
virusfre
recombin
solubl
gb
might
explain
observ
would
like
highlight
fact
ph
endosom
dramat
impair
stain
hcmv
gb
epitop
damag
least
short
time
period
minut
data
shown
analyz
hcmvinfect
mddc
tem
observ
intact
particl
embed
vesicl
lowdens
content
figur
taken
togeth
result
provid
strong
evid
hcmv
particl
sequest
earli
endosom
intact
virion
hcmv
one
largest
anim
virus
nm
diamet
consid
size
hcmv
particl
base
observ
conclud
endocyt
pathway
see
review
except
macropinocytosi
could
involv
hcmv
intern
mddc
inde
herp
virus
epsteinbarr
herplex
simplex
viru
shown
endocytos
larg
uncoat
vesicl
involv
mechan
suggest
role
macropinosom
analyz
mddc
figur
intern
hcmv
virion
partial
co
local
confoc
imag
perform
immobil
immatur
mddc
incub
two
hour
ice
vhle
strain
moi
subsequ
cultur
three
hour
hour
b
cell
fixedpermeabil
immunostain
indic
column
antibodi
green
antihcmv
gb
red
imag
obtain
lsm
meta
zeiss
germani
singl
confoc
plane
present
merg
panel
green
red
stain
intens
directli
analyz
along
virtual
section
indic
thin
white
line
imagej
rgb
profil
plugin
result
display
graph
right
xaxi
distanc
pixel
yaxi
fluoresc
intens
white
arrowhead
indic
small
cmv
aggreg
isol
particl
c
x
hcmvinfect
mddc
vhle
moi
subject
three
consecut
subcellular
fraction
step
sucros
percol
gradient
harvest
earli
late
endosomeenrich
lysosomeenrich
fraction
earli
endosom
ee
late
endosom
le
enrich
fraction
first
pool
eel
eel
lysosom
ly
enrich
fraction
concentr
use
western
blot
analysi
use
hcmv
gb
mcp
antibodi
recombin
hcmv
gb
franc
use
posit
control
molecular
weight
gb
kda
kda
mcp
pn
mean
post
nuclear
fraction
two
hour
postinfect
high
magnif
tem
notic
hcmv
particl
form
close
larg
uncoat
vesicl
figur
use
pharmacolog
inhibitor
macropinocytosi
treat
mddc
infect
hcmv
amilorid
wellknown
na
h
exchang
inhibitor
also
wide
use
select
blocker
fluidphas
endocytosi
fpe
macropinocytosi
endotheli
cell
mddc
addit
amilorid
test
effect
pkc
inhibitor
infect
mddc
hcmv
shown
figur
amilorid
mm
nm
significantli
reduc
infect
rate
dosedepend
manner
obtain
result
rottlerin
suplementari
figur
confirm
concentr
amilorid
mm
use
effici
block
macropinocytosi
da
fitcdextran
mddc
data
shown
furthermor
tem
analysi
amiloridetr
mddc
infect
hcmv
clearli
show
particl
one
dock
plasma
membran
figur
note
despit
document
efficaci
amilorid
studi
amilorid
treatment
promot
minor
chang
number
size
filipodialik
structur
mddc
compar
previou
publish
result
obtain
epitheli
cell
quantif
observ
show
impair
macropinocytosi
capabl
mddc
result
strong
defect
entri
hcmv
cell
figur
final
chlorpromazin
clathrindepend
endocytosi
inhibitor
effect
infect
rate
even
highest
concentr
mm
figur
altogeth
result
show
hcmv
particl
intern
mddc
macropinocyticlik
pathway
previous
demonstr
dcsign
necessari
hcmv
dock
mddc
plasma
membran
moreov
sever
studi
shown
dcsign
organ
cholesterolenrich
microdomain
plasma
membran
immatur
live
mddc
thu
hypothes
hcmv
intern
could
involv
cholesterolenrich
lipid
raft
confirm
hypothesi
disrupt
cholesterolcontain
microdomain
mddc
increas
dose
methylbcyclodextrin
mbcd
methyl
cyclic
oligosaccharid
abl
solubil
cholesterol
remov
plasma
membran
cell
cultur
hcmv
two
hour
infect
rate
calcul
describ
earlier
observ
cholesterol
deplet
significantli
decreas
infect
mddc
compar
cell
treat
vehicl
prove
cholesterolenrich
microdomain
essenti
intern
hcmv
cell
figur
ensur
type
microdomain
involv
endocyt
process
lead
hcmv
infect
also
test
whether
filipin
nystatin
complex
cholesterol
lipid
raft
extract
inhibit
hcmv
infect
mddc
neither
filipin
nystatin
effect
infect
rate
compar
vehicletr
cell
figur
result
rather
unexpect
sinc
filipin
nystatin
disturb
cholesterolenrich
microdomain
howev
accord
previou
studi
report
filipin
nystatin
may
effici
inhibit
cholesteroldepend
endocytosi
even
case
may
enhanc
result
demonstr
hcmv
intern
also
depend
cholesterolenrich
microdomain
among
virus
infect
mammalian
cell
requir
endosom
acidif
effici
releas
capsid
cytoplasm
step
commonli
defin
viral
penetr
howev
case
herp
simplex
viru
ebola
sar
coronaviru
low
ph
suffici
induc
fusion
viral
envelop
endocyt
vesicl
membran
recent
report
endotheliotrop
hcmv
strain
also
known
product
infect
mddc
use
phindepend
fast
endocyt
pathway
entri
endotheli
cell
base
observ
wonder
whether
infect
mddc
hcmv
depend
decreas
endosom
ph
address
question
pretreat
immatur
mddc
ammonium
chlorid
buffer
nh
cl
bafilomycin
stabil
endocyt
ph
buffer
ph
block
vatpas
respons
endosom
ph
decreas
respect
incub
hcmv
ammonium
chlorid
bafilomycin
pretreat
effect
rate
mddc
infect
comparison
vehicl
alon
figur
base
tem
observ
pretreat
mddc
nm
impair
hcmv
intern
figur
subsequ
step
infect
process
describ
previous
paper
inde
quantif
hcmv
particl
outsid
insid
mddc
nontreat
mddc
reveal
differ
figur
result
strongli
suggest
immatur
dc
report
milder
endosom
acidif
macrophag
matur
dc
lead
less
antigen
degrad
process
consist
peptideload
capac
mhc
molecul
therefor
wonder
whether
hcmv
virion
sequest
endosom
mddc
protect
degrad
assess
whether
accumul
virion
retain
potenti
infect
tri
recov
hcmv
particl
endosomeenrich
fraction
eel
unfortun
unabl
recov
viral
particl
without
induc
irrevers
damag
particl
demonstr
absenc
infect
hff
cell
cultur
subcellular
fraction
data
shown
therefor
use
transinfect
experiment
assay
previous
describ
incub
mddc
monocytederiv
macrophag
monocyt
blood
donor
hcmv
two
hour
infect
cell
extens
wash
pb
lowph
inactiv
buffer
place
hff
analyz
amount
infect
hff
note
test
cell
mddc
macrophag
monocyt
allow
infect
report
cell
regardless
whether
cell
pretreat
dmso
bafilomycin
figur
left
panel
lowph
wash
monocyt
abl
infect
hff
spite
bafilomycin
treatment
figur
right
panel
suggest
effect
observ
pb
wash
due
virion
stick
plasma
membran
importantli
lowph
wash
supplementari
figur
macrophag
pretreat
dmso
fail
transinfect
hff
inhibit
endosom
acidif
impair
transinfect
figur
right
panel
suggest
endosom
acidif
may
lead
degrad
viral
particl
infect
macrophag
confirm
previou
result
pretreat
bafilomycin
follow
lowph
wash
abrog
transinfect
hff
cell
infect
mddc
figur
right
panel
tend
reduc
result
confirm
infect
mddc
like
transmit
hcmv
particl
close
contact
membranebound
virion
plasma
membran
target
cell
primari
mechan
transinfect
interestingli
result
agreement
work
falcon
colleagu
show
macropinosom
human
dc
uniqu
organel
abl
regul
exocytos
also
show
acid
wash
cell
free
virion
stick
plasma
membran
still
abl
transinfect
hff
abil
may
due
protect
hcmv
particl
destruct
mild
control
endosom
acidif
character
immatur
dc
human
cytomegaloviru
infect
replic
broad
array
cell
type
reflect
patholog
epidemiolog
hcmv
diseas
dendrit
cell
postul
role
system
spread
viru
aim
character
mechan
hcmv
internalizationentri
mddc
inde
method
entri
hcmv
cell
shown
differ
cell
type
also
viral
strain
accord
produc
howev
noth
known
hcmv
enter
mddc
purpos
use
imag
techniqu
well
biochem
function
assay
use
pharmacolog
inhibitor
block
success
step
hcmv
infect
use
transmiss
electron
microscopi
observ
open
close
filopodialik
structur
close
contact
hcmv
particl
awar
addit
experi
use
focus
ion
beamscan
electron
microscopi
would
requir
definit
conclud
type
cellular
structur
involv
cmv
entri
mddc
moreov
technolog
would
also
inform
conclus
appreci
statu
cmv
particl
tem
imag
present
studi
nevertheless
observ
virion
accumul
vesicl
usual
moder
even
markedli
dens
electron
suggest
observ
accumul
locat
within
cell
also
virion
accumul
vesicl
vari
densiti
ultrastructur
studi
present
articl
show
hcmvcontain
uncoat
vesicl
resembl
macropinosom
term
size
nm
diamet
content
other
shown
hcmv
entri
human
retin
pigment
epitheli
cell
occur
invagin
cell
membran
viral
particl
coat
plasma
membran
dendrit
cell
engulf
antigen
intracellular
vesicl
actindepend
pathway
demonstr
actin
polymeris
indispens
mediat
engulf
hcmv
endocyt
compart
mddc
actindepend
infect
pathway
also
observ
other
retin
pigment
epitheli
endotheli
cell
human
foreskin
fibroblast
infect
shown
independ
actin
like
hcmv
shown
enter
fibroblast
direct
fusion
plasma
membran
cellular
factor
involv
viru
entri
macropinocytosi
identifi
sever
envelop
virus
vaccinia
viru
hcmv
studi
show
hcmv
entri
subsequ
event
ie
express
immedi
earli
ie
earli
e
viral
antigen
mddc
involv
activ
actindepend
remodel
plasma
membran
also
depend
na
h
exchang
pkc
activ
integr
cholesterolenrich
microdomain
provid
strong
evid
conclud
hcmv
infect
process
mddc
fulfil
criteria
defin
macropinocytosi
previous
defin
other
conclus
consist
previou
studi
report
similar
hcmv
endocyt
pathway
endotheli
cell
anoth
commonli
use
viral
strain
e
chose
focu
studi
vhle
strain
basi
inhous
data
show
often
higher
infecti
potenti
toward
mddc
entdotheliotrop
strain
although
infecti
potenti
may
also
vari
mddc
prepar
given
strain
content
macropinosom
either
degrad
late
endosomelysosom
stage
recycl
plasma
membran
yet
unknown
mechan
see
review
analyz
locat
intern
hcmv
virion
observ
accumul
envelop
hcmv
particl
earli
endosom
compart
reach
plateau
six
hour
postinfect
lead
product
infect
endocytosi
envelop
virus
must
follow
fusion
viral
envelop
endocyt
vesicl
membran
observ
uncoat
capsid
simultan
close
nuclear
envelop
interestingli
also
notic
possibl
associ
nake
capsid
fiberlik
structur
consid
microtubul
sinc
microtubul
polymer
inhibitor
nocodazol
colchicin
inhibit
iee
antigen
express
cmvinfect
mddc
data
shown
work
accord
paper
show
cmv
kaposi
sarcoma
associ
viru
use
microtubul
network
convey
uncoat
capsid
nucleu
recent
clearli
shown
contrast
requir
drop
ph
macrophag
endosom
dendrit
cell
abl
tune
endosom
ph
keep
stabl
tightli
regul
reactiv
oxygen
speci
ro
h
balanc
endolysosom
dc
stabl
endosom
ph
allow
mild
proteolysi
lead
effici
antigen
process
instead
complet
protein
hydrolysi
observ
direct
fusion
hcmv
envelop
mddc
plasma
membran
transmiss
electron
microscopi
rather
earli
time
point
minut
pi
low
ph
gene
cluster
requir
facilit
penetr
stage
tr
strain
epitheli
endotheli
cell
fibroblast
shown
infect
independ
receptor
evid
cell
typespecif
receptor
could
explain
hcmv
infect
mddc
phdepend
vhle
contain
gene
cluster
shown
still
capabl
infect
mddc
propos
two
hypothes
explain
phindepend
fusion
firstli
rule
virus
contain
heterogen
particl
contain
gene
miss
these
gene
would
allow
particl
ie
bear
gene
product
rapidli
enter
infect
mddc
other
would
intern
would
unabl
promot
fusion
thu
prone
accumul
macropinosomelik
vesicl
hypothesi
agreement
result
publish
recent
paper
secondli
hcmv
viru
known
adapt
host
phindepend
fusion
might
anoth
exampl
adapt
tempt
postul
hcmv
evolv
use
endocyt
machineri
effici
penetr
dc
without
entir
destroy
investig
need
elabor
hypothes
use
subcellular
fraction
western
blot
analys
show
envelop
capsid
compon
gb
mcp
still
detect
nativ
fulllength
protein
lowand
intermediatedens
endosom
like
earli
late
endosom
interestingli
falcon
colleagu
alreadi
describ
similar
macropinosomelik
vesicl
capabl
intern
concentr
particul
antigen
latex
bead
renam
enlargeosom
addit
qpcr
analys
viral
dna
separ
fraction
indic
presenc
cmv
genom
test
fraction
supplementari
figur
observ
suggest
fusion
intern
virion
might
occur
late
endosom
stage
human
mddc
previous
demonstr
dcsign
instrument
specif
immobil
hcmv
particl
mddc
plasma
membran
allow
infect
base
antibodymedi
neutral
cmv
bind
dcsign
conclud
interact
account
bind
capac
mddc
cmv
previou
report
alreadi
shown
lowph
buffer
strongli
alter
dcsign
oligomer
probabl
also
abil
bind
high
affin
cognat
ligand
cmv
gb
although
admit
acid
wash
inactiv
cmv
particl
bind
plasma
membran
fibroblast
endotheli
cell
observ
made
mddc
provid
altern
explan
acid
buffermedi
inactiv
plasma
membranestuck
cmv
particl
experiment
model
inde
acid
wash
may
also
promot
strip
cmv
virion
outsid
mddc
supplementari
figur
paper
clearli
show
stabl
endosom
ph
within
infect
mddc
protect
hcmv
virion
degrad
without
impair
mddc
infect
therefor
differ
fate
macropinosom
describ
earlier
observ
context
hcmv
entri
mddc
lead
infect
cell
capabl
transinfect
interestingli
recent
paper
tacken
collegu
show
bind
neck
region
dcsign
use
monoclon
antibodi
induc
endocytosi
clathrin
independ
result
prolong
local
dcsign
earli
endosom
compart
hand
target
dcsign
region
anticdr
region
lead
late
endosom
compart
dcsign
either
membraneassoci
oligom
solubl
counterpart
clearli
key
role
hcmv
infect
mddc
locat
cholesterolenrich
lipid
raft
dcsign
microdomain
shown
essenti
hiv
intern
mddc
inde
cholesterol
deplet
plasma
membran
microdomain
microdomain
disrupt
lead
disrupt
dcsign
cluster
surfac
express
dcsign
singl
molecul
cluster
thought
drastic
impair
high
affin
interact
lectin
ligand
lead
blockag
viral
entri
data
total
agreement
observ
show
destruct
microdomain
use
methylbcyclodextrin
significantli
impair
mddc
infect
therefor
demonstr
nanosc
molecular
dcsign
cluster
locat
cholesterolenrich
lipid
raft
also
essenti
hcmv
intern
macropinocytosi
cholesteroldepend
tempt
hypothes
simpl
interact
dcsign
hcmv
could
suffici
induc
macropinocytosi
via
activ
dcsigndepend
signal
knowledg
would
first
document
receptorspecif
macropinocytosismedi
process
viru
entri
howev
supplement
experi
need
determin
import
process
cellular
biolog
dc
hcmvinfect
mddc
shown
releas
infecti
hcmv
day
infect
vhle
paper
show
hour
postinfect
late
antigen
even
express
endosom
protect
virion
releas
captur
particul
remain
infecti
sinc
abl
transinfect
highli
permiss
fibroblast
appear
hcmv
evolv
use
highli
endocyt
properti
immatur
dc
monocyt
monocytederiv
macrophag
benefit
therefor
propos
besid
latent
replic
virus
third
pool
cmv
might
exist
cellprotect
viral
pool
abl
spread
bodi
stowaway
take
advantag
migratori
properti
dc
essenti
use
dc
trojan
hors
observ
restrit
cmv
infect
mddc
interestingli
hiv
particl
captur
dcsignexpress
cell
remain
stabl
infecti
sever
day
inde
immatur
dcmediat
hiv
transinfect
also
shown
mediat
exocytosi
captur
hiv
particl
exocytosedparticl
harbor
exosom
antigen
intern
hcv
viru
like
particl
also
protect
lysosom
degrad
whithin
immaturedc
infect
cell
abl
transinfect
cell
studi
detect
particl
insid
mddc
hour
postinfect
previou
work
group
gwendalyn
randolph
show
murin
dc
abl
migrat
peripher
tissu
lymph
node
within
hour
assum
upon
intern
infecti
cmv
particl
entri
site
exampl
oropharyng
anogenit
mucosa
resid
dc
may
undergo
maturationmigr
program
like
lead
releas
still
infecti
particl
critic
locat
human
organ
within
less
day
conclus
data
indic
hcmv
may
taken
advantag
macropinocytosi
major
process
captur
antigen
mild
endosom
acidif
human
immatur
dendrit
cell
allow
protect
hcmv
virion
initi
product
viral
infect
figur
intern
hcmv
virion
coloc
wherea
recombin
solubl
hcmv
gb
confoc
imag
particul
intact
hcmv
particl
solubl
recombin
hcmv
gb
mddc
costain
hcmv
gb
red
green
mddc
incub
minut
intact
hcmv
particl
vhle
strain
moi
upper
row
result
display
lower
row
show
immunostain
hcmv
gb
red
green
obtain
mddc
incub
solubl
recombin
hcmv
gb
mgml
franc
set
report
b
costain
hcmv
gb
red
transferrin
receptor
green
alexafluor
transferrin
mddc
incub
recombin
solubl
hcmv
gb
imag
obtain
lsm
leica
microsystem
germani
dic
imag
display
left
side
immunostain
singl
confoc
plane
present
scale
bar
indic
dic
pictur
tif
figur
hcmv
intern
mddc
impair
larg
spectrum
pkc
inhibitor
mddc
preincub
rottlerin
shown
block
pkc
activ
rottlerin
mm
compar
vehicl
dmso
prior
cultur
cell
viru
vhle
moi
two
hour
cell
prepar
analyz
describ
legend
figur
n
independ
experi
three
differ
donor
total
tif
figur
acid
wash
treatment
allow
strip
hcmv
particl
mddc
plasma
membran
tem
pictur
mddc
incub
vhle
hcmv
particl
middl
right
panel
moi
noninfect
left
panel
infect
cell
wash
either
lowph
buffer
glycin
ph
pb
alon
extens
rins
process
describ
black
arrow
indic
infecti
hcmv
virion
b
quantif
infecti
hcmv
particl
tem
immobil
plasma
membran
white
bar
intern
vacuol
black
bar
hcmvinfect
mddc
two
hour
vhle
moi
wash
glycinebas
acid
buffer
glycin
ph
pb
alon
n
cell
per
condit
result
repres
least
two
independ
experi
tif
